BAUSSS biomarker improves melanoma survival risk assessment

Author:

Dixon Anthony J.12ORCID,Steinman Howard K.3ORCID,Nirenberg Alexander1ORCID,Zouboulis Christos C.4ORCID,Sladden Michael5ORCID,Popescu Catalin6,Anderson Stuart17ORCID,Longo Caterina89ORCID,Thomas J. Meirion10

Affiliation:

1. Australasian College of Cutaneous Oncology Docklands Victoria Australia

2. American Osteopathic College of Dermatology Kirksville Missouri USA

3. Campbell University School of Osteopathic Medicine Lillington North Carolina USA

4. Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau Brandenburg Medical School Theodor Fontane Dessau Germany

5. University of Tasmania Launceston Tasmania Australia

6. Carol Davila University of Medicine and Pharmacy Bucharest Romania

7. Maffra Medical Group Maffra Victoria Australia

8. Department of Dermatology University of Modena and Reggio Emilia Modena Italy

9. Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia Skin Cancer Center Reggio Emilia Italy

10. Formerly of Royal Marsden Hospital Chelsea UK

Abstract

AbstractBackgroundThe American Joint Committee on Cancer (AJCC) method of staging melanoma is dated and inaccurate. It ignores important prognostic melanoma features, especially the patient's age. BAUSSS is more accurate in determining survival risk for primary cutaneous melanoma patients who have no clinical or imaging evidence of nodal or distant metastases. BAUSSS is an algorithm incorporating analysis of Breslow thickness, Age, Ulceration, Subtype of melanoma, Sex and Site. These are the six features from the patient history along with the details from the melanoma pathology report that are most predictive of mortality outcome.ObjectiveTo develop a single‐page document that allows the clinician to determine BAUSSS biomarker‐predicted prognosis in consultation with the patient.MethodFrom various data sources, we developed an algorithm to predict melanoma mortality using the BAUSSS biomarker system. The single‐page algorithm was made available to download at https://globalmelanoma.net/bausss‐survival‐chart, thus being readily available without charge to all clinicians and their patients.ResultsBAUSSS method of determining melanoma prognosis is more accurate and less costly than the AJCC staging system. The only surgery the patient requires is wide local excision of the primary tumour. This method of ascertaining melanoma risk does not require added surgery, costs, hospitalization, tests and anaesthesia, such as would be required if sentinel lymph node biopsy was undertaken. BAUSSS can be a useful tool in determining which primary melanoma patients are at sufficiently high risk to be considered for adjuvant drug therapy.ConclusionWe encourage clinicians to download and print in colour this single‐page BAUSSS mortality prediction tool, laminate it, and use it face to face with the patient in consultations. Not only will the patient be able to recognize his/her long‐term prognosis but will also be able to see how their tumour severity compares with others.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3